Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer Long-Term Benefits of Adjuvant Abemaciclib in Breast Cancer

Adding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news